1762 Stock Overview
Chunghwa Chemical Synthesis & Biotech Co., Ltd. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 1/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
My Notes
Capture your thoughts, links and company narrative
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$33.85 |
| 52 Week High | NT$58.20 |
| 52 Week Low | NT$32.90 |
| Beta | 0.76 |
| 1 Month Change | -12.08% |
| 3 Month Change | -19.69% |
| 1 Year Change | -41.03% |
| 3 Year Change | -47.84% |
| 5 Year Change | -5.31% |
| Change since IPO | -54.87% |
Recent News & Updates
Why Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 22
Chunghwa Chemical Synthesis & Biotech (TWSE:1762) Has A Somewhat Strained Balance Sheet
Nov 14Recent updates
Why Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Shaky Earnings Are Just The Beginning Of Its Problems
Nov 22Chunghwa Chemical Synthesis & Biotech (TWSE:1762) Has A Somewhat Strained Balance Sheet
Nov 14Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TWSE:1762) Business And Shares Still Trailing The Industry
Aug 09Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Dividend Is Being Reduced To NT$0.80
Jul 12Chunghwa Chemical Synthesis & Biotech's (TWSE:1762) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Apr 04A Look At The Intrinsic Value Of Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762)
Apr 01Chunghwa Chemical Synthesis & Biotech Co., Ltd.'s (TPE:1762) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Mar 04What To Know Before Buying Chunghwa Chemical Synthesis & Biotech Co., Ltd. (TPE:1762) For Its Dividend
Jan 28Should You Rely On Chunghwa Chemical Synthesis & Biotech's (TPE:1762) Earnings Growth?
Jan 02The Chunghwa Chemical Synthesis & Biotech (TPE:1762) Share Price Is Up 131% And Shareholders Are Boasting About It
Dec 06Shareholder Returns
| 1762 | TW Pharmaceuticals | TW Market | |
|---|---|---|---|
| 7D | -5.7% | -4.1% | -0.6% |
| 1Y | -41.0% | -4.9% | 28.5% |
Return vs Industry: 1762 underperformed the TW Pharmaceuticals industry which returned -4.9% over the past year.
Return vs Market: 1762 underperformed the TW Market which returned 28.5% over the past year.
Price Volatility
| 1762 volatility | |
|---|---|
| 1762 Average Weekly Movement | 2.8% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in TW Market | 7.9% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 1762 has not had significant price volatility in the past 3 months compared to the TW market.
Volatility Over Time: 1762's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1964 | n/a | Chung-Hsin Huang | www.ccsb.com.tw |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. engages in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs) in Taiwan and the United States. It offers API products, which include immunosuppressant, oncology, anti-virus, immunomodulating agents, and other products, as well as peptide drugs.
Chunghwa Chemical Synthesis & Biotech Co., Ltd. Fundamentals Summary
| 1762 fundamental statistics | |
|---|---|
| Market cap | NT$2.63b |
| Earnings (TTM) | NT$97.62m |
| Revenue (TTM) | NT$1.52b |
26.9x
P/E Ratio1.7x
P/S RatioIs 1762 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 1762 income statement (TTM) | |
|---|---|
| Revenue | NT$1.52b |
| Cost of Revenue | NT$1.04b |
| Gross Profit | NT$473.52m |
| Other Expenses | NT$375.90m |
| Earnings | NT$97.62m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.26 |
| Gross Margin | 31.22% |
| Net Profit Margin | 6.44% |
| Debt/Equity Ratio | 30.0% |
How did 1762 perform over the long term?
See historical performance and comparisonDividends
2.4%
Current Dividend Yield64%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/18 00:35 |
| End of Day Share Price | 2024/12/18 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Chunghwa Chemical Synthesis & Biotech Co., Ltd. is covered by 9 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yenya Kuo | Capital Securities Corporation |
| Ryan Liu | IBTS Investment Consulting Co., Ltd. |
| Zhennan Lee | Jih Sun Securities Investment Consulting Co., Ltd. |